NDAORALCAPSULE, EXTENDED RELEASE
Approved
Aug 2021
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
10
Data completeness
7/8 — Comprehensive
LOREEV XR (lorazepam) by Almatica Pharma is gamma-aminobutyric acid-a (gaba a ) receptors in the brain and enhances gaba-mediated synaptic inhibition. Approved for epilepsy, status epilepticus, anxiety disorders. First approved in 2021.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LOREEV XR is an extended-release oral benzodiazepine formulation of lorazepam that enhances GABA-mediated synaptic inhibition in the brain. It is indicated for epilepsy, anxiety disorders, agitation, and psychotic conditions including schizophrenia and bipolar disorder. The extended-release capsule formulation (approved August 2021) offers improved dosing convenience over immediate-release alternatives.
$0.001BPart D
Peak7.7 years to LOEProduct is in peak commercial phase with modest Part D penetration (~3,000 claims in 2023); team size likely stable with maintenance-focused commercial strategy.
Mechanism of Action
gamma-aminobutyric acid-A (GABA A ) receptors in the brain and enhances GABA-mediated synaptic inhibition.
Pharmacologic Class:
Benzodiazepine
Indications (3)
Worked on LOREEV XR at Almatica Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.